Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer

Publication date: Available online 5 November 2017
Source:Practical Radiation Oncology
Author(s): Kentaro Ishii, Toshiko Yamanaga, Ryo Ogino, Yukinari Hosokawa, Shun Kishimoto, Ryuta Nakahara, Chiaki Shimada, Ryu Kawamorita, Takuhito Tada, Yoshiki Hayashi, Toshifumi Nakajima
PurposeThis study aimed to compare bowel and urinary health-related quality of life (HRQOL) between prostate-only (PO) volumetric-modulated arc therapy (VMAT) and whole-pelvic (WP) VMAT in patients with localized prostate cancer.Methods and MaterialsA total of 234 patients treated with definitive VMAT to 78Gy in 39 fractions were enrolled. Of these, 108 patients received PO-VMAT, and 126 patients received initial WP-VMAT to 46.8Gy in 26 fractions using a simultaneous integrated boost technique. HRQOL was prospectively assessed before radiotherapy (baseline), and 3, 6, 12, and 24months after treatment using the Expanded Prostate Cancer Index Composite (EPIC).ResultsBaseline HRQOL scores did not differ significantly between the two groups. No significant between-group differences in HRQOL change from baseline were observed for all bowel and urinary EPIC domains. The proportion of patients showing a clinically relevant decrease in bowel and urinary HRQOL scores from baseline was similar between the groups throughout the follow-up period. An analysis of individual HRQOL items showed that patients undergoing WP-VMAT were more likely to report moderate/big problems with bloody stools (P=.039) and overall bowel problems (P=.008) than those undergoing PO-VMAT at 12months. However, there was no significant between-group difference in any individual items at 24months.ConclusionsBowel and urinary HRQOL is largely similar for patients receiving PO-VMAT and WP-VMAT during 24months of follow-up, with the only differences seen in responses to specific bowel HRQOL items at 12months.



http://ift.tt/2zepFid